A special article following the relicence of aprotinin injection in Europe

Anaesth Crit Care Pain Med. 2017 Apr;36(2):97-102. doi: 10.1016/j.accpm.2017.02.001. Epub 2017 Feb 13.

¹ Cardiothoracic anaesthesia, critical care and pain, Royal Brompton and Harefield NHS foundation trust, Harefield hospital, Harefield, UK. Electronic address: d.royston@rbht.nhs.uk.
² Department of anesthesiology, Ghent University, Ghent university hospital, De Pintelaan 185, 9000 Ghent, Belgium.
³ Thoraxkliniken/Department of cardiothoracic surgery & anesthesiology, Karolinska institutet, Karolinska university hospital, 17176 Stockholm, Sweden.
⁴ Department of anaesthesia and critical care II, CHU de Bordeaux, 33600 Pessac, France; INSERM, biology of cardiovascular diseases, U1034, university Bordeaux, 33600 Pessac, France.
⁵ Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.

No abstract available

Keywords: Aprotinin; Benefit-Risk analysis; Conditions of use; Nordic Aprotinin Patient Registry (NAPaR); Relicense.

Publication types